レイクフロント・バイオセラピューティクス
Galapagos N.V. Sponsored ADR
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | 0.03 | $12M | $0 |
| 2026 Q1 | 0.22 | $6M | -$83M |
| 2025 Q4 | 11.87 | $901M | -$49M |
| 2025 Q3 | -3.07 | $71M | -$65M |
| 2025 Q2 | -1.60 | $65M | -$113M |
| 2025 Q1 | -2.33 | $75M | — |
| 2024 Q4 |
| 0.29 |
| $75M |
| — |
| 2024 Q3 | -0.74 | $60M | — |